GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Beneish M-Score

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Beneish M-Score : -3.03 (As of Jun. 02, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.03 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shenzhen Hepalink Pharmaceutical Group Co's Beneish M-Score or its related term are showing as below:

HKSE:09989' s Beneish M-Score Range Over the Past 10 Years
Min: -8.43   Med: -2.3   Max: 74.3
Current: -3.03

During the past 13 years, the highest Beneish M-Score of Shenzhen Hepalink Pharmaceutical Group Co was 74.30. The lowest was -8.43. And the median was -2.30.


Shenzhen Hepalink Pharmaceutical Group Co Beneish M-Score Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Beneish M-Score Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.84 -2.12 -2.43 -2.20 -2.95

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.45 -2.50 -2.61 -2.95 -3.03

Competitive Comparison of Shenzhen Hepalink Pharmaceutical Group Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Hepalink Pharmaceutical Group Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's Beneish M-Score falls into.



Shenzhen Hepalink Pharmaceutical Group Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shenzhen Hepalink Pharmaceutical Group Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0386+0.528 * 1.0226+0.404 * 1.1019+0.892 * 0.8051+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9149+4.679 * -0.116125-0.327 * 0.9055
=-3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was HK$1,363 Mil.
Revenue was 1491.766 + 1511.973 + 1448.511 + 1544.285 = HK$5,997 Mil.
Gross Profit was 514.583 + 500.672 + 414.649 + 549.059 = HK$1,979 Mil.
Total Current Assets was HK$11,340 Mil.
Total Assets was HK$20,504 Mil.
Property, Plant and Equipment(Net PPE) was HK$2,844 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$0 Mil.
Selling, General, & Admin. Expense(SGA) was HK$608 Mil.
Total Current Liabilities was HK$5,012 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,956 Mil.
Net Income was 168.42 + -1013.307 + 21.261 + 62.138 = HK$-761 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = HK$0 Mil.
Cash Flow from Operations was 956.438 + 691.492 + 331.212 + -359.606 = HK$1,620 Mil.
Total Receivables was HK$1,631 Mil.
Revenue was 1481.857 + 1970.145 + 1829.997 + 2166.618 = HK$7,449 Mil.
Gross Profit was 517.138 + 663.066 + 577.247 + 756.367 = HK$2,514 Mil.
Total Current Assets was HK$14,120 Mil.
Total Assets was HK$23,490 Mil.
Property, Plant and Equipment(Net PPE) was HK$2,799 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$0 Mil.
Selling, General, & Admin. Expense(SGA) was HK$825 Mil.
Total Current Liabilities was HK$5,848 Mil.
Long-Term Debt & Capital Lease Obligation was HK$2,967 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1363.379 / 5996.535) / (1630.593 / 7448.617)
=0.227361 / 0.218912
=1.0386

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2513.818 / 7448.617) / (1978.963 / 5996.535)
=0.337488 / 0.330018
=1.0226

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11340.244 + 2844.148) / 20503.909) / (1 - (14120.277 + 2799.202) / 23489.518)
=0.30821 / 0.279701
=1.1019

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5996.535 / 7448.617
=0.8051

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2799.202)) / (0 / (0 + 2844.148))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(607.758 / 5996.535) / (825.115 / 7448.617)
=0.101352 / 0.110774
=0.9149

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1955.66 + 5011.869) / 20503.909) / ((2967.406 + 5848.055) / 23489.518)
=0.339815 / 0.375293
=0.9055

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-761.488 - 0 - 1619.536) / 20503.909
=-0.116125

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shenzhen Hepalink Pharmaceutical Group Co has a M-score of -3.06 suggests that the company is unlikely to be a manipulator.


Shenzhen Hepalink Pharmaceutical Group Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Business Description

Traded in Other Exchanges
Address
No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.
Executives
Orbimed Capital Llc 2102 Investment manager
Morgan Stanley & Co. International Plc 2105 Underwriter
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Avict Global Holdings Limited 2101 Beneficial owner
Worldwide Healthcare Trust Plc 2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Headlines

No Headlines